Trial · NCT07288151
MDMA-Assisted Massed Exposure Therapy for PTSD
NCT07288151, Phase 2, Recruiting, Emory University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MDMA-Assisted Massed Exposure Therapy for PTSD. Trials, record NCT07288151. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07288151
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MDMA-Assisted Massed Exposure Therapy for PTSD
- NCT number
- NCT07288151
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Emory University
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE)
- First posted
- 2025-12-17
- Last updated
- 2026-05-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in PTSD symptoms measured by CAPS-5-R | Baseline, 1 month post-treatment | The CAPS-5-R is a structured clinical interview used to assess PTSD symptoms based on DSM-5 criteria. Each symptom is rated on frequency and intensity * Combined into a severity score per item * Total score reflects overall PTSD symptom severity |
| Secondary | Changes in PTSD symptoms measured by PCL-5 | Baseline, 1 month post treatment | The PCL-5 is a 20-item self-report questionnaire used to measure PTSD symptoms based on DSM-5 criteria. Participants rate how much they've been bothered by each symptom in relation to a specific traumatic event, using a scale from 0 ("Not at all") to 4 ("Extremely"). A total score of 33 or higher indicates clinically elevated PTSD symptoms |
| Secondary | Change in PHQ questionnaire scores | Baseline, 1 month post-treatment | The PHQ-9 is a questionnaire used to assess depression severity. Each of the 9 items is scored from 0 to 3, giving a total score between 0 and 27. Higher scores suggest more severe depressive symptoms. |
| Other | Changes in fMRI-based neural activation patterns | Day 1 of treatment, Day 10 of treatment | Participants will view 15 blocks of fearful face stimuli and 15 blocks of neutral face stimuli, with emotion condition randomly interweaved. Within each block, 8 face stimuli will be presented for 500 ms each, followed by a 500 ms intertrial interval. Changes in fMRI-based neural activation patterns following MDMA-assisted massed exposure therapy will be reported. |
| Other | Changes in fear extinction retention | Day 4, Day 10 of treatment | This will be assessed via a Pavlovian fear conditioning/extinction paradigm in which colored shapes are presented visually and paired with a 250 millisecond air blast. Changes in fear extinction retention following MDMA-assisted massed exposure therapy will be reported |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07288151
GET https://conductscience.org/api/trials/v1/NCT07288151/registered